Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOALS: Oxaloacetate in ALS
NCT04204889Phase 1Completed
- Sponsor
- Omar Jawdat
- Start
- Mar 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaloacetate in amyotrophic lateral sclerosis (ALS), sponsored by Omar Jawdat. Primary endpoint: Dose Limiting Toxicities at Day 28. Started Mar 2020; status: completed.
02
Drugs
oxaloacetate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04204889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204889.